Segment Information (Schedule of Total Revenues of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended		3 Months Ended		9 Months Ended		0 Months Ended		3 Months Ended		9 Months Ended		0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013 drug	Sep. 30, 2012 Successor [Member]	Sep. 30, 2013 Successor [Member]	Sep. 30, 2013 Successor [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Propafenone Rythmol Sr [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Propafenone Rythmol Sr [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Propafenone Rythmol Sr [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Other [Member]		Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Other [Member]		Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Other [Member]		Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member]		Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member]		Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member]		Sep. 30, 2012 Successor [Member] Strativa [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member]	Sep. 30, 2012 Successor [Member] Strativa [Member] Megace ES [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Megace ES [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Megace ES [Member]	Sep. 30, 2012 Successor [Member] Strativa [Member] Nascobal Nasal Spray [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Nascobal Nasal Spray [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Nascobal Nasal Spray [Member]	Sep. 30, 2012 Successor [Member] Strativa [Member] Other [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Other [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member] Other [Member]	Sep. 30, 2012 Successor [Member] Strativa [Member] Other product related royalty streams [Member]		Sep. 30, 2013 Successor [Member] Strativa [Member] Other product related royalty streams [Member]		Sep. 30, 2013 Successor [Member] Strativa [Member] Other product related royalty streams [Member]		Sep. 28, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Propafenone Rythmol Sr [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Propafenone Rythmol Sr [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other [Member]		Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other [Member]		Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member]		Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member]		Sep. 28, 2012 Predecessor [Member] Strativa [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Megace ES [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Megace ES [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Nascobal Nasal Spray [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Nascobal Nasal Spray [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other product related royalty streams [Member]		Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues		$ 10,689	$ 267,321	$ 791,186	$ 10,689	$ 249,818	$ 737,733	$ 0	$ 54,952	$ 150,382	$ 0	$ 26,343	$ 20,116	$ 0	$ 19,423	$ 53,919	$ 0	$ 12,277	$ 45,206	$ 0	$ 11,450	$ 31,268	$ 0	$ 11,079	$ 41,725	$ 0	$ (225)	$ 22,530	$ 0	$ 5,283	$ 42,296	$ 10,689	[1]	$ 102,013	[1]	$ 308,094	[1]	$ 0	[2]	$ 7,223	[2]	$ 22,197	[2]	$ 0	$ 17,503	$ 53,453	$ 0	$ 9,455	$ 31,009	$ 0	$ 7,592	$ 20,596	$ 0	$ (398)	$ (877)	$ 0	[2]	$ 854	[2]	$ 2,725	[2]	$ 238,063	$ 803,868	$ 218,614	$ 742,890	$ 33,046	$ 104,543	$ 2,772	$ 9,353	$ 17,237	$ 54,217	$ 45,875	$ 156,593	$ 12,695	$ 36,059	$ 0	$ 0	$ 32,683	$ 90,166	$ 0	$ 0	$ 67,908	[1]	$ 273,503	[1]	$ 6,398	[2]	$ 18,456	[2]	$ 19,449	$ 60,978	$ 12,279	$ 38,670	$ 6,382	$ 17,693	$ 0	$ 0	$ 788	[2]	$ 4,615	[2]
Number of other insignificant generic drugs	50

[1] The further detailing of revenues of the other approximately 50 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the nine-month periods ended September 30, 2013 and 2012.

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.